Kyowa Kirin Co., Ltd.

Consolidated Financial Summary (IFRS)
Fiscal 2026 Third Quarter

(January 1, 2026 – September 30, 2026)

This document is an English translation of the Japanese-language original.

SUMMARY OF CONSOLIDATED FINANCIAL STATEMENTS (IFRS)
for Nine Months Ended September 30, 2026

November 2, 2026

Company Name: Kyowa Kirin Co., Ltd.
Listed Exchanges: Tokyo Stock Exchange
Stock Code: 4151
President & Chief Executive Officer: Abdul Mullick
Telephone: +81 3 5205 7206
Inquiries: Naohiko Kubo
Executive Officer
Director, Finance Department
URL: https://www.kyowakirin.com/index.html
Scheduled start date of dividend payment: –
Appendix materials to accompany the financial report: Yes
Results presentation meeting: Yes (for institutional investors and securities analysts)

(Millions of yen rounded off)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2026

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Core operating profit		Profit before tax		Profit		Core profit		Profit attributable to owners of parent	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	384,947	10.2	96,952	46.8	64,728	35.1	51,673	58.5	77,398	72.2	51,673	58.5
September 30, 2025	349,451	(3.7)	66,062	(11.2)	47,924	(33.0)	32,599	(41.7)	44,936	(25.1)	32,599	(41.7)

Total comprehensive income: Nine months ended September 30, 2026: ¥50,058 million; 92.5%
Nine months ended September 30, 2025: ¥25,998 million; (60.7)%

Note: Core base performance indicators have been redefined as of the fiscal year ending December 31, 2026. Core operating profit is calculated by deducting SG&A (excl. amortization of intangible assets) and R&D from gross profit, and further excluding non-recurring items as determined by the Company. Core profit is calculated by deducting income tax expenses related to the core operating profit from the core operating profit. Note that the figures for the nine months ended September 30, 2025 are calculated based on the consolidated results incorporating these changes.

	Basic earnings per share	Diluted earnings per share	Basic core earnings per share
Nine months ended	Yen	Yen	Yen
September 30, 2026	98.70	–	147.83
September 30, 2025	62.28	62.28	85.85

Note: Diluted earnings per share for the nine months ended September 30, 2026 is not stated because there are no potential shares.

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2026	1,088,380	908,543	908,543	83.5
December 31, 2025	1,107,860	893,332	893,332	80.6

2. Dividends

	Dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2025	–	30.00	–	32.00	62.00
Fiscal year ending December 31, 2026	–	35.00	–		
Fiscal year ending December 31, 2026 (Forecast)				35.00	70.00

Note: Revisions to the dividend forecast most recently announced: None

3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2026 (from January 1, 2026 to December 31, 2026)

(Percentages indicate year-on-year changes.)

	Revenue		Core operating profit		Profit before tax		Profit		Basic earnings per share	Core profit		Basic core earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen	Millions of yen	%	Yen
Full year	520,000	4.7	130,000	18.4	95,000	8.9	75,000	11.9	143.27	103,000	22.0	196.76

Note: Changes to the earnings forecasts most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period under review: Yes

Excluded: one company Orchard Therapeutics Limited

(2) Changes in accounting policies, and accounting estimates:

a. Changes in accounting policies required by IFRS: No

b. Changes in accounting policies other than a. above: No

c. Changes in accounting estimates: Yes

Note: Please refer to “Changes in accounting estimates” under “(5) Notes to Condensed Quarterly Consolidated Financial Statements” in “2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto” on page 23 of the attachment.

(3) Number of shares issued (ordinary shares)

a. Number of shares issued (including treasury shares)

As of September 30, 2026	525,634,500 shares
As of December 31, 2025	525,634,500 shares

b. Number of treasury shares

As of September 30, 2026	2,049,790 shares
As of December 31, 2025	2,146,320 shares

c. Average number of shares during the period

Nine months ended September 30, 2026	523,546,281 shares
Nine months ended September 30, 2025	523,440,518 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None

* Notice regarding the appropriate use of the earnings forecasts and other special comments
  The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.

Attachment Index

1. Summary of Business Performance and Financial Position 5
(1) Summary of Quarterly Consolidated Financial Position 5
(2) Summary of Quarterly Consolidated Business Performance 6
(3) Summary of Quarterly Consolidated Cash Flows 10
(4) Research and Development Activities 11
(5) Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements 15
2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto 16
(1) Condensed Quarterly Consolidated Statement of Financial Position 16
(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income 18
(3) Condensed Quarterly Consolidated Statement of Changes in Equity 20
(4) Condensed Quarterly Consolidated Statement of Cash Flows 22
(5) Notes to Condensed Quarterly Consolidated Financial Statements 23
Segment information 23
Notes on going concern assumption 23
Changes in accounting estimates 23
Changes in presentation 23
Cash flow information 23


1. Summary of Business Performance and Financial Position

(1) Summary of Quarterly Consolidated Financial Position

(Billions of yen)

	As of December 31, 2025	As of September 30, 2026	Change from previous fiscal year-end
Assets	1,107.9	1,088.4	(19.5)
Non-current assets	614.5	605.8	(8.7)
Current assets	493.3	482.6	(10.8)
Liabilities	214.5	179.8	(34.7)
Equity	893.3	908.5	15.2
Ratio of equity attributable to owners of parent to total assets (%)	80.6%	83.5%	2.9%

- Assets as of September 30, 2026, were ¥1,088.4 billion, a decrease of ¥19.5 billion compared to the end of the previous fiscal year.
  - Non-current assets fell by ¥8.7 billion compared to the end of the previous fiscal year, to ¥605.8 billion, due mainly to decreases in intangible assets and goodwill following the transfer of the established pharmaceuticals joint venture in EMEA, despite an increase in property, plant and equipment.
  - Current assets decreased by ¥10.8 billion compared to the end of the previous fiscal year, to ¥482.6 billion, due mainly to a decrease in trade and other receivables, despite increases in cash and cash equivalents and other current assets.
- Liabilities as of September 30, 2026, were ¥179.8 billion, a decrease of ¥34.7 billion compared to the end of the previous fiscal year, due mainly to decreases in trade and other payables and other current liabilities, despite an increase in income taxes payable.
- Equity as of September 30, 2026, was ¥908.5 billion, an increase of ¥15.2 billion compared to the end of the previous fiscal year, due mainly to an increase due to the recording of profit attributable to owners of parent, despite a decrease due to the payment of dividends.
  As a result, the ratio of equity attributable to owners of parent to total assets as of September 30, 2026 was 83.5%, an increase of 2.9 percentage points compared to the end of the previous fiscal year.



(2) Summary of Quarterly Consolidated Business Performance

1) Overview of results

The Company has redefined core base performance indicators as of the fiscal year ending December 31, 2026.

New core operating profit is calculated by deducting SG&A (excl. amortization of intangible assets) and R&D from gross profit, and further excluding non-recurring items as determined by the Company. Compared to the conventional core operating profit, this excludes amortization of intangible assets (amortization of sales rights), share of profit or loss of investments accounted for using the equity method, and non-recurring gains or losses that the Company deems should be excluded.

New core profit is calculated by deducting income tax expenses related to the new core operating profit from the new core operating profit.

New core earnings per share are calculated by dividing new core profit by the average number of shares during the period. For the nine months ended September 30, 2026 and the nine months ended September 30, 2025, the Company did not exclude any items as non-recurring gains or losses, as determined by the Company.

Furthermore, the core operating profit, core profit, and core earnings per share for the nine months ended September 30, 2025, as described below, also reflect this change in definition.

(Billions of yen)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Year-on-year change	Rate of change (%)
Revenue	349.5	384.9	35.5	10.2%
Core operating profit	66.1	97.0	30.9	46.8%
Profit before tax	47.9	64.7	16.8	35.1%
Profit	32.6	51.7	19.1	58.5%
Basic earnings per share (Yen)	62.28	98.70	36.42	58.5%
Core profit	44.9	77.4	32.5	72.2%
Basic core earnings per share (Yen)	85.85	147.83	61.98	72.2%

<Average exchange rates for each period>

Currency	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Year-on-year change
USD (USD/¥)	¥149	¥159	¥10
GBP (GBP/¥)	¥195	¥213	¥18
EUR (EUR/¥)	¥165	¥185	¥20

For the nine months ended September 30, 2026 (January 1, 2026 to September 30, 2026), revenue was ¥384.9 billion (up 10.2% compared to the same period of the previous fiscal year), and core operating profit was ¥97.0 billion (up 46.8%). In addition, profit was ¥51.7 billion (up 58.5%).

- Revenue increased, driven by the growth of global strategic products, mainly in North America and EMEA, as well as increased revenue from technology out-licensing. The positive effect on revenue from foreign exchange was ¥19.8 billion.
- Core operating profit increased due mainly to an increase in gross profit associated with increased revenue from overseas regions and technology out-licensing, in addition to a decrease in research and development expenses. The positive effect on core operating profit from foreign exchange was ¥8.5 billion.
- Profit increased due mainly to an increase in core operating profit, despite an increase in other expenses resulting from the recording of loss on contracts and impairment losses.


2) Revenue by regional control function

(Billions of yen)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Year-on-year change	Rate of change (%)
Japan	89.7	83.7	(6.0)	(6.7)%
North America	129.9	148.5	18.6	14.3%
EMEA	62.4	62.8	0.4	0.7%
Others	67.5	90.0	22.5	33.3%
Total consolidated revenue	349.5	384.9	35.5	10.2%

Notes:
1. Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).
2. EMEA consists of Europe, the Middle East, Africa, etc.
3. Others consists of revenue from technology out-licensing, the APAC revenue, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc.

Composition of revenue by regional control function



<Revenue by product>

(Billions of yen)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Year-on-year change	Rate of change (%)
Crysvita	146.7	171.5	24.8	16.9%
Poteligeo	33.7	38.8	5.1	15.2%
Libmeldy/Lenmeldy	4.4	7.3	2.9	65.6%
PHOZEVEL	5.9	7.1	1.1	19.2%
Duvroq	10.9	12.8	1.9	17.3%
G-Lasta	13.7	10.5	(3.1)	(22.8)%
Romiplate	11.5	9.0	(2.5)	(22.1)%


- Despite growth in Crysvita, a treatment for FGF23-related diseases, and Duvroq, a treatment for renal anemia, revenue in Japan was down year on year due mainly to a decline in revenue from G-Lasta, an agent for decreasing the incidence of febrile neutropenia, the impact of the transfer of manufacturing and marketing approval for Depakene and other long-listed products, and the impact of the reductions in drug price standards implemented in April 2025 and April 2026.
  - Revenue from Crysvita, a treatment for FGF23-related diseases, has been growing steadily since its launch in 2019. Furthermore, November 2025 saw the launch of the Crysvita Prefilled Syringe Formulation, a syringe-type formulation designed to simplify self-administration at home.
  - Revenue from PHOZEVEL, a treatment for hyperphosphatemia, has been growing steadily since its launch in 2024.
  - Revenue from Duvroq, a treatment for renal anemia, has been growing steadily since its launch in 2020.
  - Revenue from G-Lasta, an agent for decreasing the incidence of febrile neutropenia, decreased due to the impact of biosimilar products and the impact of the reductions in drug price standards.

- Revenue in North America increased year on year due to the growth of global strategic products.
  - Revenue from Crysvita, a treatment for X-linked hypophosphatemia, has been growing steadily since its launch in 2018.
  - Revenue from Poteligeo, an anticancer agent, has been growing since its launch in 2018.
  - KOMZIFTI (generic name: ziftomenib) was approved by the U.S. Food and Drug Administration (FDA) in November 2025 and launched in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a sensitive NPM1 mutation and no satisfactory alternative treatment options. Profits will be shared 50:50 in the United States in accordance with the strategic collaboration agreement with Kura Oncology. The Company recognizes net profit or loss after profit sharing as revenue when positive and as selling, general and administrative expenses when negative. For the nine months ended September 30, 2026, net profit or loss was negative and is therefore recorded as selling, general, and administrative expenses.

- Revenue in EMEA increased year on year due to the growth of global strategic products, despite the reactionary decline from one-time revenue recorded in the same period of the previous fiscal year.
  - Revenue from Crysvita, a treatment for X-linked hypophosphatemia, has been growing since its launch in 2018, as the number of countries where it has been released and its indications have expanded.
  - Revenue from Poteligeo, an anticancer agent, has been growing as the number of countries where it has been released has been increasing since its launch in 2020.
  - As a result of Kyowa Kirin International plc transferring the residual assets related to the established medicines business to Grünenthal in February 2026, royalties decreased in line with sales. Additionally, there was a reactionary decline due to the recording of revenue of ¥6.1 billion (£30.6 million) from the transfer of the rights (intellectual property) for one brand of established medicines to the joint venture in the same period of the previous fiscal year.

- Revenue from Others increased year on year.
  - Revenue from Libmeldy/Lenmeldy, a treatment for metachromatic leukodystrophy (MLD), grew steadily. In addition, in December 2025, metachromatic leukodystrophy (MLD) was added to the Recommended Uniform Screening Panel (RUSP) in the United States.
  - Revenue from technology out-licensing increased due to an increase in sales royalties from AstraZeneca in relation to benralizumab, as well as the recognition as revenue of the full amount of contract liabilities associated with the partnership agreement with Amgen for KHK4083/AMG 451 (rocatinlimab) following the termination of that agreement.

3) Core operating profit




- Core operating profit increased year on year due to an increase in gross profit and a decrease in research and development expenses, despite an increase in selling, general and administrative expenses.

(3) Summary of Quarterly Consolidated Cash Flows

(Billions of yen)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Year-on-year change	Rate of change (%)
Net cash provided by (used in) operating activities	69.6	86.3	16.7	24.0%
Net cash provided by (used in) investing activities	(41.6)	(26.6)	15.0	(36.0)%
Net cash provided by (used in) financing activities	(33.6)	(38.1)	(4.5)	13.5%
Cash and cash equivalents at beginning of period	244.7	218.8	(25.9)	(10.6)%
Cash and cash equivalents at end of period	240.2	241.1	0.9	0.4%

- Cash and cash equivalents as of September 30, 2026 were ¥241.1 billion, an increase of ¥22.3 billion compared with the balance of ¥218.8 billion as of December 31, 2025.
  The main contributing factors affecting cash flow during the nine months ended September 30, 2026 were as follows:
- Net cash provided by operating activities was ¥86.3 billion, compared with net cash provided by operating activities of ¥69.6 billion in the same period of the previous fiscal year. The major inflows were profit before tax of ¥64.7 billion, a decrease in trade receivables of ¥40.7 billion, depreciation and amortization of ¥23.1 billion, and impairment losses (reversal of impairment losses) of ¥6.5 billion. Major outflows were a decrease in contract liabilities of ¥9.9 billion and income taxes refund (paid) of ¥8.0 billion.
- Net cash used in investing activities was ¥26.6 billion, compared with net cash used in investing activities of ¥41.6 billion in the same period of the previous fiscal year. Major outflows were purchase of property, plant and equipment of ¥26.2 billion and purchase of intangible assets of ¥4.8 billion. A major inflow was ¥5.4 billion in proceeds from sale of investments in subsidiaries following the transfer of the established pharmaceuticals joint venture in EMEA.
- Net cash used in financing activities was ¥38.1 billion, compared with net cash used in financing activities of ¥33.6 billion in the same period of the previous fiscal year. A major outflow was dividends paid of ¥35.1 billion.



(4) Research and Development Activities

The Group continuously and actively invests management resources in research and development activities. In accordance with the Story for Vision 2030 formulated in 2024, in research, the Group has designated bone and mineral, intractable hematological diseases/hemato oncology, and rare diseases as focus disease areas. The Group aims to continually create life-changing value by seeking to concentrate resources in areas where it can leverage its expertise, while strengthening research into innovative modalities, including advanced antibody technologies and hematopoietic stem cell gene therapy. To achieve this, the Group is working to sustainably achieve drug discovery in line with its strategy by strengthening in-house research capabilities under an R&D structure that cuts across Japanese and overseas locations, and by promoting open innovation with external partners. In development, the Group aims to maximize product value by utilizing strategic collaboration with external partners in addition to self-driven global expansion, while steadily delivering pharmaceuticals to patients who need them. The Group will steadily deliver the life-changing value thus created to patients and seek to achieve sustainable growth.

For the nine months ended September 30, 2026, the Group's research and development expenses totaled ¥67.7 billion.

<Development status of major development products>

As of September 30, 2026

Code Name, Generic Name	Indication	Development status
ziftomenib	Acute Myeloid Leukemia (AML) (as monotherapy or in combination; in newly diagnosed and relapsed/refractory patients)	Already marketed as KOMZIFTI (US); Ph I / II / III clinical studies ongoing for label expansion
OTL-203	Mucopolysaccharidosis type IH (Hurler syndrome)	Pivotal study (Equivalent to Ph III study): in progress
KK8398, infigratinib	Achondroplasia	Ph III clinical study: in progress
	Hypochondroplasia	Ph III clinical study: preparation underway
KHK4951, tivozanib	Neovascular Age-related Macular Degeneration (nAMD)	Ph II clinical study: in progress
	Diabetic Macular Edema (DME)	Ph II clinical study: in progress
OTL-201	Mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)	PoC study (Equivalent to Ph I / II study): in progress
KK4277	Systemic Lupus Erythematosus (SLE)/Cutaneous Lupus Erythematosus (CLE)	Ph I clinical study: completed
KK2260	Advanced or metastatic solid tumors	Ph I clinical study: in progress
KK2269	Advanced or metastatic solid tumors	Ph I clinical study: in progress
KK2845	Acute Myeloid Leukemia (AML) and other Hematologic Malignancies	Ph I clinical study: in progress
KK8123	X-linked Hypophosphatemia (XLH)	Ph I / II clinical study: in progress
KK3910	Essential Hypertension	Ph I clinical study: in progress
OTL-200, atidarsagene autotemcel	Early-onset Metachromatic Leukodystrophy (MLD)	Already marketed as Libmeldy (Europe) /Lenmeldy (US) Ph III clinical study (JP): preparation underway NDA (JP): Filed
KK2223	Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-cell Lymphoma (PTCL)	Ph I clinical study: in progress
KK8005	X-linked Hypophosphatemia (XLH)	Ph I / II clinical study: in progress
KK4408	Autoimmune disease	Ph I / II clinical study: in preparation

- Ziftomenib (Product name in the U.S.: KOMZIFTI™) is an oral menin inhibitor in development by Kura Oncology, Inc. for the treatment of genetically defined acute myeloid leukemia (AML) patients with high unmet need. In November 2024, Kura Oncology and Kyowa Kirin entered into a global strategic collaboration to develop and commercialize ziftomenib in acute leukemias. Under the terms of the agreement, the companies will jointly develop and commercialize ziftomenib. Kura Oncology, Inc. will lead development, regulatory and commercial strategy in the U.S. Outside the U.S., Kyowa Kirin will lead development, regulatory and commercial strategy. In November 2025, the U.S. Food and Drug Administration (FDA) granted full approval of ziftomenib for the treatment of adult patients with relapsed or refractory (R/R) AML with an NPM1 mutation. Ziftomenib is now being evaluated in multiple ongoing clinical trials aimed at expanding its use across broader AML patient populations. These include: the Phase III KOMET-017 trial of ziftomenib in combination with intensive or non-intensive chemotherapy in newly diagnosed AML; the Phase I KOMET-007 trial of ziftomenib in combination with intensive or non-intensive chemotherapy in patients with R/R or newly diagnosed NPM1-m or KMT2A-r AML, as well as in combination with intensive chemotherapy and quizartinib in newly diagnosed NPM1-m/FLT3-m AML; and the Phase I KOMET-008 trial evaluating ziftomenib-based combination therapies, including ziftomenib in combination with gilteritinib in R/R NPM1-m/FLT3-m AML. Since April 2026, a Phase II clinical trial in Japan has been underway for patients with R/R NPM1-m AML. In August 2026, ziftomenib received orphan drug designation in Japan for the treatment of AML with NPM1-m or KMT2A-r.

- OTL-203 is an investigational HSC gene therapy in development for the treatment of mucopolysaccharidosis type IH (Hurler syndrome). Orchard Therapeutics is currently implementing a registrational study (equivalent to a Phase III clinical study) of OTL-203 as a therapy to potentially correct the underlying cause of Hurler syndrome.

- KK8398 (infigratinib) is a small-molecular FGFR3 inhibitor, which has been developed for bone diseases by QED Therapeutics, wholly owned by BridgeBio. In February 2024, the Company entered into a partnership wherein QED Therapeutics grants Kyowa Kirin an exclusive license to develop and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. A Phase III clinical trial for achondroplasia is ongoing in Japan. The Company is currently preparing for a Phase III clinical trial for hypochondroplasia in Japan. In June 2026, KK8398 (infigratinib) received orphan drug designation in Japan for the treatment of achondroplasia without closed growth plates. In August 2026, we received orphan drug designation in Japan for the treatment of hypochondroplasia in patients without closed growth plates.

- Tivozanib, the active ingredient of KHK4951 is a small-molecule vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor (TKI) discovered and developed by Kyowa Kirin. KHK4951 is a novel nano-crystalized tivozanib eye drops designed to deliver it efficiently to the posterior ocular tissues and has the potential to provide a novel non-invasive treatment option for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Phase II clinical studies are ongoing. In September 2026, we disclosed topline data from a Phase II study in nAMD.

- OTL-201 is an investigational HSC gene therapy in development for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome). A proof-of-concept (Equivalent to a Phase I / II study) is ongoing.

- KK4277 is an optimized antibody based on antibodies licensed from SBI Biotech. It has been enhanced with antibody-dependent cell-mediated cytotoxicity (ADCC) activity using our POTELLIGENT technology. A Phase I study in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) has been completed, and the future development strategy is currently being considered based on the results obtained.

- KK2260 is an EGFR-TfR1 bispecific antibody developed using the Company's proprietary bispecific antibody technology REGULGENT. It is designed as an antibody that achieves selective iron depletion in cancer cells, and in non-clinical trials it showed high efficacy and tolerability. A Phase I clinical trial is ongoing.

- KK2269 is an EpCAM-CD40 bispecific antibody developed using the Company's proprietary bispecific antibody technology REGULGENT. It is designed as an antibody that activates only antigen-presenting cells near the tumor by cross-linking EpCAM, which is highly expressed in various tumors, with CD40 on antigen-presenting cells. In non-clinical trials, it was found to exhibit the therapeutic effects of anti-tumor immunity while suppressing systemic side effects. A Phase I clinical trial is ongoing.

- KK2845 is the Company's first antibody-drug conjugate (ADC). The target molecule is TIM-3, a Phase I clinical trial for acute myeloid leukemia (AML) and other Hematologic Malignancies is ongoing.

- KK8123 is a human antibody targeting FGF23. A Phase I / II study for XLH is ongoing.

- KK3910 is an antibody developed by Kyowa Kirin. A Phase I clinical trial for healthy adults and essential hypertension is ongoing.

- OTL-200 (atidarsagene autotemcel, Product name in the U.S.: Lenmeldy, Product name in Europe: Libmeldy) is an investigational HSC gene therapy aimed at correcting the underlying genetic cause of Metachromatic Leukodystrophy (MLD). OTL-200 received designation as an orphan regenerative medicine product for early-onset MLD in Japan in October 2025. The NDA was filed in Japan in March 2026 and the Company is preparing a Phase III clinical trial in Japan.

- KK2223 is an in-house-discovered antibody-drug conjugate (ADC). A Phase I clinical study for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) is ongoing in NA.

- KK8005 is an antibody developed by Kyowa Kirin. A Phase I / II clinical study in patients with X-linked hypophosphatemia (XLH) is ongoing.

- KK4408 is an in-house antibody leveraging our proprietary bispecific antibody technology, REGULGENT. A Phase I / II clinical study in autoimmune diseases is in preparation.

R&D pipeline

small molecule　antibody　HSC-GT　　Updated since Jun. 30, 2026

As of Sep. 30, 2026

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	[In-House or Licensed] Remarks
			PhI / PhII / PhIII	
KK8123 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia	PhI	[In-House] Clinical study is being conducted in NA and EU as a global product
KK8398 infigratinib Oral	FGFR3 Inhibitor	Achondroplasia	PhI / PhII / PhIII	[QED Therapeutics] Clinical study is being conducted in JP Orphan Drug Designation in JP
		Hypochondroplasia		Preparation underway for Ph Ⅲ clinical trial in JP Orphan Drug Designation in JP
ziftomenib ※ Oral	Menin Inhibitor	Acute Lymphoblastic Leukemia (ALL) (Monotherapy)	PhI	[Kura Oncology] Clinical study is being conducted in NA and EU as a global product KMT2A-rearranged ALL KOMET-001
		Acute Myeloid Leukemia (AML) (Monotherapy)	PhI	Clinical study is being conducted in NA and EU as a global product Non-NPM1-mutant AML/Non-KMT2A-rearranged AML KOMET-001
			PhI / PhII	Adult Relapsed or Refractory AML with a NPM1 Mutation Ph Ⅱ clinical study is being conducted in JP Orphan Drug Designation in JP
		Acute Myeloid Leukemia (AML) (Combination)	PhI	Clinical study is being conducted in NA as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-007
			PhI	Clinical study is being conducted in NA as a global product FLT3/NPM1 co-mutated AML Combinations with cytarabine + daunorubicin, and quizartinib KOMET-007
			PhI	Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML/KMT2A-rearranged AML/FLT3-mutant AML Combinations with gilteritinib, FLAG-IDA, LDAC KOMET-008
			PhI / PhII / PhIII	Clinical study is being conducted as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine (for NPM1-mutant only) , and cytarabine + daunorubicin KOMET-017
KK2845	Anti-TIM-3 ADC	Acute Myeloid Leukemia (AML) and other Hematologic Malignancies	PhI	[In-House] Antibody-Drug Conjugate Clinical study is being conducted in JP as a global product
OTL-203	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IH (Hurler Syndrome)	PhI / PhII / PhIII	[In-House] Rare Pediatric Disease (RPD), Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU
OTL-201	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IIIA (Sanfilippo Syndrome type A)	PhI / PhII Ph I / Ph Ⅱ	[In-House] Rare Pediatric Disease (RPD) designation (FDA) Orphan Drug Designation (FDA, EMA) Innovation Passport Designation (MHRA)
KHK4951 tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Diabetic Macular Edema	PhI / PhII	[In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
		Neovascular Age-Related Macular Degeneration	PhI / PhII	Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
KK2260 Injection	EGFR-TfR1Bispecific Antibody	Advanced or Metastatic Solid Tumors	PhI	[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA as a global product
KK2269 Injection	EpCAM-CD40Bispecific Antibody	Advanced or Metastatic Solid Tumors	PhI	[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product

As of Sep. 30, 2026

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
			PhI	PhII	PhIII	
KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus				[SBI Biotech] POTELLIGENT Clinical study is completed in JP and Asia
KK3910 Injection		Essential Hypertension				[In-House] Clinical study is being conducted in JP as a global product
OTL-200 atidarsagene autotemcel	Hematopoietic Stem Cell (HSC) Gene Therapy	Early-onset Metachromatic Leukodystrophy (MLD)				[In-House] Orphan Regenerative Medicine Product Designation in JP A Ph.3 clinical study in JP is under preparation Product Name in US: Lenmeldy Product Name in Europe: Libmeldy
KK2223		Cutaneous T cell lymphoma Peripheral T cell lymphoma	✓			[In-House] Antibody-Drug Conjugate Clinical study is being conducted for Ph I in NA Clinical study is preparing for Ph I in EU
KK8005		X-linked Hypophosphatemia	✓			[In-House] Clinical study is being conducted for Ph I / II in JP as a global product
KK4408		autoimmune disease				[In-House] REGULGENT Clinical study is preparing for Ph I / II

※ For detailed information on ziftomenib(Product Name in US: KOMZIFTI)'s development status, please refer to Kura Oncology's website. https://kuraoncology.com/

Note: On October 6, 2026, dosing of KK4408 commenced for the first patient in the Phase I / II study in Japan targeting autoimmune diseases.

Major Applications and Approvals

Code Name, Generic Name, Product Name	Indication	Application/ Under Review	Countries/ Regions Received Approval in 2026
OTL-200 (atidarsagene autotemcel, product name in the U.S.: Lenmeldy; product name in Europe: Libmeldy)	Early-onset Metachromatic Leukodystrophy (MLD)	Application filed in Japan	—

(5) Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements

No revisions have been made to the consolidated earnings forecasts announced on May 7, 2026.

2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Condensed Quarterly Consolidated Statement of Financial Position

(Millions of yen)

	As of December 31, 2025	As of September 30, 2026
Assets		
Non-current assets		
Property, plant and equipment	141,225	147,566
Goodwill	183,497	179,067
Intangible assets	201,415	189,951
Investments accounted for using equity method	9,244	9,515
Other financial assets	16,566	17,451
Retirement benefit asset	21,164	21,444
Deferred tax assets	32,052	32,872
Other non-current assets	9,349	7,925
Total non-current assets	614,512	605,789
Current assets		
Inventories	67,440	65,206
Trade and other receivables	181,205	143,117
Other financial assets	1,054	780
Other current assets	24,880	31,870
Cash and cash equivalents	218,769	241,114
Subtotal	493,348	482,087
Assets held for sale	–	503
Total current assets	493,348	482,591
Total assets	1,107,860	1,088,380

(1) Condensed Quarterly Consolidated Statement of Financial Position (continued)

(Millions of yen)

	As of December 31, 2025	As of September 30, 2026
Equity		
Share capital	26,745	26,745
Capital surplus	427,733	427,766
Treasury shares	(5,585)	(5,387)
Retained earnings	406,321	422,508
Other components of equity	38,117	36,910
Total equity attributable to owners of parent	893,332	908,543
Total equity	893,332	908,543
Liabilities		
Non-current liabilities		
Liabilities from application of equity method	2,190	3,473
Retirement benefit liability	280	242
Provisions	4,414	4,494
Deferred tax liabilities	387	443
Other financial liabilities	22,283	19,463
Other non-current liabilities	3,896	1,443
Total non-current liabilities	33,450	29,558
Current liabilities		
Trade and other payables	125,041	100,147
Provisions	3,938	2,036
Other financial liabilities	8,836	4,933
Income taxes payable	9,668	18,856
Other current liabilities	33,595	24,307
Total current liabilities	181,078	150,278
Total liabilities	214,528	179,837
Total equity and liabilities	1,107,860	1,088,380

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

Condensed Quarterly Consolidated Statement of Profit or Loss

(Millions of yen)

	January 1, 2025 to September 30, 2025	January 1, 2026 to September 30, 2026
Revenue	349,451	384,947
Cost of sales	(90,061)	(96,583)
Gross profit	259,390	288,364
Selling, general and administrative expenses	(116,433)	(123,714)
Research and development expenses	(76,835)	(67,698)
Amortization of intangible assets	(5,114)	(8,821)
Share of profit (loss) of investments accounted for using equity method	985	662
Other income	749	1,003
Other expenses	(14,740)	(30,941)
Finance income	3,132	7,705
Finance costs	(3,209)	(1,831)
Profit before tax	47,924	64,728
Income tax expense	(15,326)	(13,055)
Profit	32,599	51,673
Profit attributable to		
Owners of parent	32,599	51,673
Earnings per share		
Basic earnings per share (Yen)	62.28	98.70
Diluted earnings per share (Yen)	62.28	–

Note: Diluted earnings per share for the nine months ended September 30, 2026 is not stated because there are no potential shares.

Condensed Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	January 1, 2025 to September 30, 2025	January 1, 2026 to September 30, 2026
Profit	32,599	51,673
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	(139)	(175)
Share of other comprehensive income of investments accounted for using equity method	–	6
Total of items that will not be reclassified to profit or loss	(139)	(169)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(6,196)	(1,684)
Share of other comprehensive income of investments accounted for using equity method	(266)	238
Total of items that may be reclassified to profit or loss	(6,462)	(1,446)
Other comprehensive income	(6,601)	(1,615)
Comprehensive income	25,998	50,058
Comprehensive income attributable to		
Owners of parent	25,998	50,058

(3) Condensed Quarterly Consolidated Statement of Changes in Equity

January 1, 2025 to September 30, 2025

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Share acquisition rights	Exchange differences on translation of foreign operations
Balance at January 1, 2025	26,745	427,733	(5,887)	371,050	27	30,661
Profit	–	–	–	32,599	–	–
Other comprehensive income	–	–	–	–	–	(6,462)
Total comprehensive income	–	–	–	32,599	–	(6,462)
Dividends of surplus	–	–	–	(30,882)	–	–
Purchase of treasury shares	–	–	(6)	–	–	–
Disposal of treasury shares	–	(8)	56	–	–	–
Share-based remuneration transactions	–	(3)	183	–	(27)	–
Transfer from other components of equity to retained earnings	–	–	–	35	–	–
Total transactions with owners	–	(10)	233	(30,847)	(27)	–
Balance at September 30, 2025	26,745	427,723	(5,654)	372,801	–	24,199

	Equity attributable to owners of parent			Total equity
	Other components of equity		Total	
	Financial assets measured at fair value through other comprehensive income	Total		
Balance at January 1, 2025	482	31,171	850,811	850,811
Profit	–	–	32,599	32,599
Other comprehensive income	(139)	(6,601)	(6,601)	(6,601)
Total comprehensive income	(139)	(6,601)	25,998	25,998
Dividends of surplus	–	–	(30,882)	(30,882)
Purchase of treasury shares	–	–	(6)	(6)
Disposal of treasury shares	–	–	48	48
Share-based remuneration transactions	–	(27)	153	153
Transfer from other components of equity to retained earnings	(35)	(35)	–	–
Total transactions with owners	(35)	(62)	(30,686)	(30,686)
Balance at September 30, 2025	309	24,507	846,123	846,123

(3) Condensed Quarterly Consolidated Statement of Changes in Equity (continued)

January 1, 2026 to September 30, 2026

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Share acquisition rights	Exchange differences on translation of foreign operations
Balance at January 1, 2026	26,745	427,733	(5,585)	406,321	–	37,693
Profit	–	–	–	51,673	–	–
Other comprehensive income	–	–	–	–	–	(1,446)
Total comprehensive income	–	–	–	51,673	–	(1,446)
Dividends of surplus	–	–	–	(35,077)	–	–
Purchase of treasury shares	–	–	(8)	–	–	–
Disposal of treasury shares	–	(2)	12	–	–	–
Share-based remuneration transactions	–	35	194	–	–	–
Transfer from other components of equity to retained earnings	–	–	–	(408)	–	–
Total transactions with owners	–	33	198	(35,486)	–	–
Balance at September 30, 2026	26,745	427,766	(5,387)	422,508	–	36,247

	Equity attributable to owners of parent			Total equity
	Other components of equity		Total	
	Financial assets measured at fair value through other comprehensive income	Total		
Balance at January 1, 2026	424	38,117	893,332	893,332
Profit	–	–	51,673	51,673
Other comprehensive income	(169)	(1,615)	(1,615)	(1,615)
Total comprehensive income	(169)	(1,615)	50,058	50,058
Dividends of surplus	–	–	(35,077)	(35,077)
Purchase of treasury shares	–	–	(8)	(8)
Disposal of treasury shares	–	–	10	10
Share-based remuneration transactions	–	–	229	229
Transfer from other components of equity to retained earnings	408	408	–	–
Total transactions with owners	408	408	(34,846)	(34,846)
Balance at September 30, 2026	663	36,910	908,543	908,543

(4) Condensed Quarterly Consolidated Statement of Cash Flows

(Millions of yen)

	January 1, 2025 to September 30, 2025	January 1, 2026 to September 30, 2026
Cash flows from operating activities		
Profit before tax	47,924	64,728
Depreciation and amortization	18,752	23,079
Impairment losses (reversal of impairment losses)	1,307	6,528
Increase (decrease) in provisions	1,530	(2,022)
Share of loss (profit) of investments accounted for using equity method	(985)	(662)
Foreign exchange loss (gain)	600	(1,698)
Decrease (increase) in inventories	70	1,945
Decrease (increase) in trade receivables	1,511	40,689
Increase (decrease) in trade payables	(1,955)	1,618
Increase (decrease) in contract liabilities	(5,845)	(9,892)
Income taxes refund (paid)	(3,112)	(8,046)
Other	9,824	(29,970)
Net cash provided by (used in) operating activities	69,623	86,298
Cash flows from investing activities		
Purchase of property, plant and equipment	(24,344)	(26,237)
Proceeds from sale of property, plant and equipment	126	92
Purchase of intangible assets	(13,005)	(4,842)
Purchase of investment securities	(1,057)	(1,037)
Proceeds from sale of investment securities	275	–
Proceeds from sale of investments in subsidiaries resulting in change in scope of consolidation	–	5,361
Proceeds from redemption of bonds of subsidiaries and associates	4,000	–
Transfers to escrow account	(7,700)	–
Other	62	26
Net cash provided by (used in) investing activities	(41,643)	(26,636)
Cash flows from financing activities		
Repayments of lease liabilities	(2,734)	(3,049)
Purchase of treasury shares	(6)	(8)
Dividends paid	(30,882)	(35,077)
Other	21	10
Net cash provided by (used in) financing activities	(33,600)	(38,124)
Effect of exchange rate changes on cash and cash equivalents	1,150	807
Net increase (decrease) in cash and cash equivalents	(4,470)	22,345
Cash and cash equivalents at beginning of period	244,681	218,769
Cash and cash equivalents at end of period	240,211	241,114

(5) Notes to Condensed Quarterly Consolidated Financial Statements

Segment information

The Group omitted information by reportable segment as the Group consists of only the one reportable segment, which is the Pharmaceuticals business.

Notes on going concern assumption

No applicable items.

Changes in accounting estimates

Changes in estimates of useful lives

On May 7, 2026, the Company announced plans to further strengthen its drug discovery capabilities by consolidating the Fuji Site (located in Nagaizumi, Suntou, Shizuoka) and the Tokyo Research Park (located in Machida, Tokyo) and relocating them to the Yokohama Business Park (located in Yokohama, Kanagawa) as a new research base.
In connection with this relocation, the useful life of buildings and structures that are not expected to be used after the move has been changed during the nine months ended September 30, 2026.
As a result, compared to the previous method, research and development expenses for the nine months ended September 30, 2026 increased by ¥441 million, and profit before tax decreased by the same amount.

Changes in presentation

Condensed Quarterly Consolidated Statement of Profit or Loss

In the nine months ended September 30, 2025, amortization of sales rights, which had been included in “Selling, general and administrative expenses,” has been presented separately as “Amortization of intangible assets” due to an increase in its monetary materiality. To reflect this change in the presentation method, the Group has reclassified the amounts in its Condensed Quarterly Consolidated Financial Statements for the nine months ended September 30, 2025.
As a result, negative ¥121,548 million in “Selling, general and administrative expenses” that was shown in the Condensed Quarterly Consolidated Statement of Profit or Loss for the nine months ended September 30, 2025, was reclassified as negative ¥116,433 million in “Selling, general and administrative expenses” and negative ¥5,114 million in “Amortization of intangible assets.”

Cash flow information

Negative ¥7,700 million in “Transfers to escrow account” during the nine months ended September 30, 2025 is a deposit made to the escrow account (account with restrictions on deposits and withdrawals) as part of the construction funds for a new biopharmaceutical drug substance manufacturing building in the U.S.